Abbott to Complete $21 Billion Acquisition of Exact Sciences, Bolstering Leadership in Cancer Diagnostics

Author | Crescent

Abbott Invests Heavily in Cancer Screening and Diagnosis.

01

Abbott's Major Acquisition Set to Close

Local time3Month20Date, Abbott announced,It is expected to2026Year3Month23Day completedExact SciencesThe AcquisitionThe announcement was made after obtaining all the necessary regulatory approvals required to complete the transaction.

According to the previously disclosed information,Abbott will pay per ordinary share105Cash Acquisition in USDExact SciencesAll outstanding shares,Total market capitalization is approximately210Billion USD, with an estimated enterprise value of230Billion US dollars。

Since the special peak during the COVID-19 period, AbbottDiagnostic services face ongoing adjustments.

The financial report shows,2025Abbott's Total Annual Sales for the Year443.28USD billion, the organic growth rate of the base business (excluding COVID-19 testing-related business) is6.7%。

2025Medical Device Sales213.87Billion USD, Year-over-Year Growth12.6%, among whichDiabetes Care Business Leads Growth；Diagnostic Department Sales89.37Billion USD, a year-on-year decline4.3%。

This transaction is expected to be completed in2026Years bring approximately30USD billion in additional sales, making Abbott2026The sales growth rate accelerated by approximately0.5%, and make2026Adjusted earnings per share for the year (EPS) Reduced by approximately0.20Dollar.

The transaction will enable Abbott to enter and lead the rapidly growing field of cancer screening and diagnostics., which is expected to boost the performance of the diagnostics sector.

TD CowenAnalystJoshua JenningsPrevious TableShow, AcquisitionExact SciencesRevitalizing Abbott's diagnostics business,And it is possible to restore the business to its pre-epidemic growth level.

02

Heavy Investment in Growth Tracks

Diagnosis Business Expected to Welcome New Opportunities

Exact SciencesIs a leader in the fields of cancer screening, precision oncology, and genetic testing, with products that can detect cancer earlier, guide treatment decisions, and monitor for recurrence.

Currently, the incidence of cancer is continuously rising globally.

According toGrand View ResearchData,2022The global cancer screening market size in year was approximately1723Billion US dollars,Expected to2030Annual growth can reach up to2936Billion US dollars。

This acquisition solidifies Abbott's leadership and strength in the diagnostics field, enabling the company to advance technologies that are more preventive, predictive, and personalized, while alsoExpands Abbott's influence in the fastest-growing areas of healthcare,

In addition, it adds a new growth area to Abbott's already high single-digit growth expectations.Established its position in the scale of600Leadership position in the US$ billion U.S. cancer screening and precision oncology diagnostics market segment。

Leerink PartnersAnalystPuneet SoudaPointed out that this transaction is "an epoch-making event" in the field of diagnostics. This also helps to enhanceDxIndustry reputation and consolidate the business model of the central laboratory.

Exact SciencesThe products includeCologuard®Detection, a market-leading non-invasive colorectal cancer screening solution;Oncotype DX®, which can provide personalized treatment decision-making basis for early breast cancer patients;Oncodetect®, which is a molecular residual disease (MRD) based on tumor information (MRD) detection, which helps identify cancer recurrence and guide subsequent treatment; andCancerguard®, which is a multi-cancer early detection blood test.

Exact SciencesWe are also advancing a series of leading next-generation cancer diagnostic product lines aimed at detecting cancer earlier, optimizing treatment decisions, and enabling regular monitoring to help people stay healthy and better manage their conditions.